Cahill Represents Envigo International Holdings in Merger with Avista Healthcare Public Acquisition (AHPA)
Cahill Gordon & Reindel LLP represented Envigo International Holdings, Inc. (Envigo), a leading early stage non-clinical contract research organization ("CRO") offering a diverse set of non-clinical discovery and safety assessment services as well as laboratory animal science tools, in connection with its transaction agreement with Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA) ("AHPAC"), a publicly traded special purpose acquisition company. Under the terms of the agreement, Envigo will become a wholly-owned subsidiary of AHPAC, which will be renamed Envigo International Holdings, Inc. and is expected to be listed on the NASDAQ stock exchange as of closing of the proposed transaction. The combined company will have an anticipated initial enterprise value of approximately $924 million.
The Cahill Corporate/M&A team was led by partners Kimberly Petillo-Décossard and Jonathan Schaffzin assisted by associates Ross Sturman, Kaitlyn Pasco, Joseph Rosati and Nikolas Rodriguez. Advice was also provided on finance matters by partners Adam Dworkin and Michael Sherman and associate, Dan Anderson, on tax by partner Craig Horowitz, counsel Ann Creed, and associate Samir Kurani, on antitrust by partner Elai Katz and counsel Lauren Rackow and associate Matt McDonagh, and on executive compensation and benefits by partner Glenn Waldrip Jr. and counsel Mark Gelman.